An interventional study of Citric acid abutment in Peri-Implantitis, Implant Infection and Microbial Disease, sponsored by Universitat Internacional de Catalunya. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-10-24.
Sponsored by Universitat Internacional de Catalunya · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya — 6 open to participants now, 6 under way, none of them phase 3. Peri-Implantitis · Universitat Internacional de Catalunya.
Among the 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya, this one is one of 2 that started in 2022, is one of 7 with no phase, and was the 10th registered.
324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.
Browse Peri-Implantitis studies →6 of the 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya are open now, in 1 country. Recruiting first, the newest first:
Universitat Internacional de Catalunya · Sites in Spain
Ages 18+ · Healthy volunteers
Universitat Internacional de Catalunya · Sites in Spain
Ages 18+ · Healthy volunteers
Universitat Internacional de Catalunya · Sites in Spain
Ages 18–80
Universitat Internacional de Catalunya · Sites in Spain
Ages 21–80 · Healthy volunteers
Universitat Internacional de Catalunya · Sites in Spain
Ages 18+
By country, each count listing its studies:
Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 2 started in 2022.
This study's planned enrollment of 36 is close to the median of 40 across 196 interventional studies indexed under Peri-Implantitis.
Median enrollment 36 across the 9 interventional studies, 143 across the 6 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Universitat Internacional de Catalunya is the lead sponsor of 151 studies on the registry; 46 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Peri-Implantitis by Universitat Internacional de Catalunya, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The use of dental implants is a predictable procedure to replace the missing tooth with high rates of success and survival. In addition, placing the abutment on the same day as the implant surgery is a safe and biologically sound procedure to minimize bone loss and peri-implant inflammation. Although citric acid antibacterial coating has never been tested in vivo, recent in vitro data support its clinical use due to its antibacterial effect at the abutment level.
This prospective randomized controlled clinical trial aims to evaluate the microbiological and inflammatory profile of implant abutments coated with citric acid.
The study population will consist on patients referred to the Department of Periodontology at Universitat Internacional de Catalunya for the replacement of missing teeth and who meet the following inclusion criteria will be included consecutively in the study.
5.3.1. Inclusion criteria
5.3.2. Exclusion criteria
The primary outcome measure will be the reduction of biofilm formation at the test abutments compared with the control abutments at the 12 weeks 6 months, 1 year and 3 year of follow-up. Biofilm formation over abutments will be quantified with Ilumina sequencing analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Antimicrobial-coated abutments (citric acid) will be allocated to the test group. Permanent Vega® (Klockner Implant System, Barcelona, Spain) will be used. The interface between implant and abutment is platform switching. The abutment height will be of 2 mm. It will be placed the day of the implant surgery and tighten to 25 N
Procedure: Citric acid abutment
Non- coated abutments (citric acid) will be allocated to the control group. Permanent Vega® (Klockner Implant System, Barcelona, Spain) will be used. The interface between implant and abutment is platform switching. The abutment height will be of 2 mm. It will be placed the day of the implant surgery and tighten to 25 N
Procedure: Citric acid abutment
The implant surgery will be performed by 3rd year residents of the Postgraduate Program in Periodontology at UIC, supervised by a board-certified periodontist (J.V). Under local anaesthesia, a mid crestal incision will be performed and a full thickness flap will be raised. Implants will be placed following the manufacturer's recommendations. Implant shoulder (IS) will be placed 1 mm subcrestally, and a distance of ≥ 1.5 mm from adjacent natural tooth and ≥ 3 mm between implants will be always respected. Implant stability will be measured with Ostell ISQ. Straight definitive abutments (2 mm height) will be tightened to 25 N respecting the previous randomization procedure. One of the implants will receive an antibacterial- coated abutment (citric acid), while the other implant will receive a non-coated abutment (C). A protector cap will be screwed manually. Implant sites will be sutured with polypropylene 5/0 (Prolene Ethicon, USA) by simple stitches.
Biofilm quantification
The primary outcome measure will be the reduction of biofilm formation at the test abutments compared with the control abutments at the 12 weeks, 6 months, 1 year and 3 years. Biofilm formation over the retrieved abutments will be quantified by means of Illumina sequencing analysis
Time frame: 12 weeks, 6 months, 1 and 3 years
Protein expression markers
Quantification of protein expressions (IL-10 beta, IL-8 and TNF-beta) for the test and control abutments. This quantification will be performed at 12 weeks, 6 months, 1 and 3 years
Time frame: 12 weeks, 6 months, 1 and 3 years
Peri-implant disease incidence
The incidence of peri-implant disease will be assessed at 1 and 3 years attending to the 2017 World Workshop Classification
Time frame: 1 and 3 years
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2022; primary completion for Oct 2025, 35 months later.
Of 121 non-industry interventional studies with no phase under Peri-Implantitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 46. This study's planned 35 months is above that.
Counting every sponsor, half of 128 studies reached it within 26 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universitat Internacional de Catalunya →